BioPharma Credit (BPCR) offers investors access to a diverse portfolio of secured debt instruments for life science companies based on BPCR’s pool of investment opportunities. The ongoing specialisation and fragmentation of the drug discovery process is translating into an increased number of market players seeking additional funding backed by sales from approved products and/or royalty streams from out-licensed products. During its IPO in March 2017 and follow-on placings, the trust ha
17 May 2018
Leading lender in life sciences
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Leading lender in life sciences
BioPharma Credit PLC USD (BPCR:LON) | 87.2 -0.6 (-0.7%) | Mkt Cap: 1,093m
- Published:
17 May 2018 -
Author:
Milosz Papst -
Pages:
18
BioPharma Credit (BPCR) offers investors access to a diverse portfolio of secured debt instruments for life science companies based on BPCR’s pool of investment opportunities. The ongoing specialisation and fragmentation of the drug discovery process is translating into an increased number of market players seeking additional funding backed by sales from approved products and/or royalty streams from out-licensed products. During its IPO in March 2017 and follow-on placings, the trust ha